OPDIVO 100MG/10 ML I.V. VIAL

INDICATIONS 1.For Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. 2.For Metastatic Melanoma Patients. 3.For Advanced Renal Cell Carcinoma Patients Who Received Prior Anti-Angiogenic Therapy. 4.For Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck on or After Platinum-Based Therapy . 5.For the Adjuvant Treatment of Patients With Melanoma With Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection. 6.For Patients With Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib. 7.For Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma Who Have Disease Progression During or Following Platinum-Based Chemotherapy. 8.For Patients (=12 years) With MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) That Has Progressed Following Treatment With a Fluoropyrimidine Oxaliplatin and Irinotecan. 9.For Adults With Relapsed or Progressed cHL After 3 or more lines thrpy